Treatment and secondary prevention of venous thromboembolism in cancer patients
| Autor: | Yu N Belenkov, Yu Yu Kirichenko, D. A. Budanova, N V Khabarova, K. V. Lobastov, G. A. Shakaryants |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Secondary prevention
medicine.medical_specialty Rivaroxaban business.industry medicine.drug_class Anticoagulant Anticoagulants Cancer Venous Thromboembolism 030204 cardiovascular system & hematology medicine.disease Dabigatran 03 medical and health sciences 0302 clinical medicine Neoplasms 030220 oncology & carcinogenesis Secondary Prevention Humans Medicine Apixaban Cardiology and Cardiovascular Medicine business Intensive care medicine Venous thromboembolism medicine.drug |
| Zdroj: | Kardiologiia. 60:71-79 |
| ISSN: | 2412-5660 0022-9040 |
| Popis: | Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|